Heron Therapeutics Executes Contract With Apexus For Non-opioid Option ZYNRELEF

(RTTNews) - Heron Therapeutics Inc. (HRTX) said that it has executed a contract for ZYNRELEF with Apexus LLC.

ZYNRELEF was approved by the U.S. Food and Drug Administration on May 12, 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.

ZYNRELEF is extended-release dual-acting local anesthetic and has been clinically shown to better manage pain, including severe pain, compared to standard-of-care bupivacaine over 72 hours and to significantly reduce or eliminate opioid use in many patients following surgery.

Apexus is the designated Prime Vendor for the 340B Drug Pricing Program, which provides drug discounts to hospitals and clinics serving vulnerable communities.

As per the deal, Heron and the Prime Vendor Program, managed by Apexus, will collaborate to lower drug pricing for participating covered entities. The two organizations are working together to assure that covered entities have access to safe and effective non-opioid postoperative pain management.